SAHA, an HDAC inhibitor, synergizes with tacrolimus to prevent murine cardiac allograft rejection

Cellular and Molecular Immunology

Volumn 9, Issue 5, 2012, Pages 390-398

  Zhang, Xin ^a   Han, Shu ^a   Kang, Yindong ^a   Guo, Meng ^b   Hong, Shanjuan ^b   Liu, Fang ^a   Fu, Shangxi ^a   Wang, Liming ^a   Wang, Quan Xing ^b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

allograft rejection; HDAC inhibitor; Th17; Treg I

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 17F; MESSENGER RNA; RETINOID RELATED ORPHAN RECEPTOR GAMMA; RETINOID RELATED ORPHAN RECEPTOR GAMMA T; STAT3 PROTEIN; TACROLIMUS; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARDIAC GRAFT REJECTION; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL POPULATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; EFFECTOR CELL; GENE EXPRESSION; IMMUNOMODULATION; IN VITRO STUDY; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SURVIVAL TIME; TH17 CELL; UPREGULATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CTLA-4 ANTIGEN; DRUG SYNERGISM; FORKHEAD TRANSCRIPTION FACTORS; HEART TRANSPLANTATION; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-17; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

ANIMALIA; MURINAE;

EID: 84866106036     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2012.28     Document Type: Article

References (52)

1. Nankivell BJ, Kuypers DR. Diagnosis and prevention of chronic kidney allograft loss. Lancet 2011; 378: 1428-1437.
2. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605-612.
3. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580-590.
4. Casey MJ, Meier-Kriesche HU. Calcineurin inhibitors in kidney transplantation: friend or foe? Curr Opin Nephrol Hypertens 2011; 20: 610-615.
5. van de Wetering J, Koumoutsakos P, Peeters A, van der Mast BJ, de Kuiper P, Ijzermans JN et al. Discontinuation of calcineurin inhibitors treatment allows the development of FOXP31 regulatory T-cells in patients after kidney transplantation. Clin Transplant 2011; 25: 40-46.
6. Li Y, Shi Y, Huang Z, Bai Y, Niu Q, Cai B et al. CNI induced Th17/Treg imbalance and susceptibility to renal dysfunction in renal transplantation. Int Immunopharmacol 2011; 11: 2033-2038.
7. Ponticelli C, Scolari MP. Calcineurin inhibitors in renal transplantation still needed but in reduced doses: A review. Transplant Proc 2010; 42: 2205-2208.
8. Zeng C, Shi X, Zhang B, Liu H, Zhang L, DingWet al. The imbalance of Th17/Th1/Tregs in patients with type 2 diabetes: Relationship with metabolic factors and complications. J Mol Med (Berl) 2011; 90: 175-186.
9. Shen Y, Tang XY, Yang YC, Ke X, Kou W, Pan CKet al. Impaired balance of Th17/Treg in patients with nasal polyposis. Scand J Immunol 2011; 74: 176-185.
10. Niu Q, Cai B, Huang ZC, Shi YY, Wang LL. Disturbed Th17/Treg balance in patients with rheumatoid arthritis. Rheumatol Int 2011; in press.
11. Hanidziar D, Koulmanda M. Inflammation and the balance of Treg and Th17 cells in transplant rejection and tolerance. Curr Opin Organ Transplant 2010; 15: 411-415.
12. Wood KJ. Regulatory T cells in transplantation. Transplant Proc 2011; 43: 2135-2136.
13. Abadja F, Sarraj B, Ansari MJ. Significance of T helper 17 immunity in transplantation. Curr Opin Organ Transplant 2012; 17: 8-14.
14. Shahbazian MD, Grunstein M. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem 2007; 76: 75-100.
15. Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007; 1: 19-25.
16. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 38-51.
17. Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 2007; 26: 5310-5318.
18. Hake SB, Xiao A, Allis CD. Linking the epigenetic 'language' of covalent histone modifications to cancer. Br J Cancer 2007; 96 Suppl: R31-R39.
19. Singh BN, Zhang G, Hwa YL, Li J, Dowdy SC, Jiang SW. Nonhistone protein acetylation as cancer therapy targets. Expert Rev Anticancer Ther 2010; 10: 935-954.
20. Roger T, Lugrin J, Le Roy D, Goy G, Mombelli M, Koessler T et al. Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood 2011; 117: 1205-1217.
21. Grabiec AM, Tak PP, Reedquist KA. Function of histone deacetylase inhibitors in inflammation. Crit Rev Immunol 2011; 31: 233-263.
22. Schildberg FA, Hagmann CA, Bohnert V, Tolba RH. Improved transplantation outcome by epigenetic changes. Transpl Immunol 2010; 23: 104-110.
23. Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, Porrett PM et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007; 13: 1299-1307.
24. Moreira JM, Scheipers P, Sorensen P. The histone deacetylase inhibitor Trichostatin A modulates CD41 T cell responses. BMC Cancer 2003; 3: 30.
25. Codd R, Braich N, Liu J, Soe CZ, Pakchung AA. Zn(II)-dependent histone deacetylase inhibitors: Suberoylanilide hydroxamic acid and trichostatin A. Int J Biochem Cell Biol 2009; 41: 736-739.
26. Marks PA, Jiang X. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 2005; 4: 549-551.
27. Marks PA, Richon VM, Miller T, Kelly WK. Histone deacetylase inhibitors. Adv Cancer Res 2004; 91: 137-168.
28. Qu W, Kang YD, Zhou MS, Fu LL, Hua ZH, Wang LM. Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells. Urol Oncol 2010; 28: 648-654.
29. Wang Q, Liu Y, Li XK. Simplified technique for heterotopic vascularized cervical heart transplantation in mice. Microsurgery 2005; 25: 76-79.
30. Xiao L, Fu ZR, Liu F, Zhang LD, Shi XM, Shen XY et al. Suppression of allograft rejection by Tim-1-Fc through cross-linking with a novel Tim-1 binding partner on T cells. PLoS ONE 2011; 6: e21697.
31. An H, Hou J, Zhou J, Zhao W, Xu H, Zheng Y et al. Phosphatase SHP-1 promotes TLRand RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1. Nat Immunol 2008; 9: 542-550.
32. Du C, Liu C, Kang J, Zhao G, Ye Z, Huang S et al. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol 2009; 10: 1252-1259.
33. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992; 357: 695-697.
34. McKinsey TA. The biology and therapeutic implications of HDACs in the heart. Handb Exp Pharmacol 2011; 206: 57-78.
35. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005; 352: 1967-1976.
36. Kinugasa F, Yamada T, Noto T, Matsuoka H, Mori H, Sudo Y et al. Effect of a new immunosuppressant histon deacetylase (HDAC) inhibitor FR276457 in a rat cardiac transplant model. Biol Pharm Bull 2008; 31: 1723-1726.
37. Wang L, de Zoeten EF, Greene MI, Hancock WW. Immunomodulatory effects of deacetylase inhibitors: Therapeutic targeting of FOXP31 regulatory T cells. Nat Rev Drug Discov 2009; 8: 969-981.
38. de Zoeten EF, Wang L, Sai H, Dillmann WH, Hancock WW. Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology 2010; 138: 583-594.
39. Saouaf SJ, Li B, Zhang G, Shen Y, Furuuchi N, Hancock WW et al. Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Exp Mol Pathol 2009; 87: 99-104.
40. de Zoeten EF, Wang L, Butler K, Beier UH, Akimova T, Sai H et al. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp31 T-regulatory cells. Mol Cell Biol 2011; 31: 2066-2078.
41. Moon C, Kim SH, Park KS, Choi BK, Lee HS, Park JB et al. Use of epigenetic modification to induce FOXP3 expression in naive T cells. Transplant Proc 2009; 41: 1848-1854.
42. Lucas JL, Mirshahpanah P, Haas-Stapleton E, Asadullah K, Zollner TM, Numerof RP. Induction of Foxp31 regulatory T cells with histone deacetylase inhibitors. Cell Immunol 2009; 257: 97-104.
43. Johnson J, Pahuja A, Graham M, Hering B, Hancock WW, Bansal-Pakala P. Effects of histone deacetylase inhibitor SAHA on effector and FOXP31 regulatory T cells in rhesus macaques. Transplant Proc 2008; 40: 459-461.
44. Liu Z, Zhang C, Sun J. Deacetylase inhibitor trichostatin A down-regulates Foxp3 expression and reduces CD41CD251 regulatory T cells. Biochem Biophys Res Commun 2010; 400: 409-412.
45. Chen N, Gao Q, Field EH. Prevention of Th1 response is critical for tolerance. Transplantation 1996; 61: 1076-1083.
46. Tay SS, Plain KM, Bishop GA. Role of IL-4 and Th2 responses in allograft rejection and tolerance. Curr Opin Organ Transplant 2009; 14: 16-22.
47. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009; 27: 485-517.
48. Bosisio D, Vulcano M, del Prete A, Sironi M, Salvi V, Salogni L et al. Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo. J Leukoc Biol 2008; 84: 1540-1548.
49. Dixon DL, Griggs KM, Bersten AD, de Pasquale CG. Systemic inflammation and cell activation reflects morbidity in chronic heart failure. Cytokine 2011; 56: 593-599.
50. Cai Y, Shen X, Ding C, Qi C, Li K, Li X et al. Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity 2011; 35: 596-610.
51. Itoh S, Nakae S, Axtell RC, Velotta JB, Kimura N, KajiwaraNet al. IL-17 contributes to the development of chronic rejection in a murine heart transplant model. J Clin Immunol 2010; 30: 235-240.
52. Harris TJ, Grosso JF, Yen HR, Xin H, Kortylewski M, Albesiano E et al. Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol 2007; 179: 4313-4317.